Brian P. Lockhart

22 Route 128, Gif Sur Yvette
Saclay, 91190, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development.

A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development.

Journal: Journal of experimental & clinical cancer research : CR

Published: December 20, 2024

Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival.

Shallow Whole-Genome Sequencing from Plasma Identifies FGFR1 Amplified Breast Cancers and Predicts Overall Survival.

Journal: Cancers

Published: April 14, 2020

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.

Journal: Cancer chemotherapy and pharmacology

Published: November 29, 2018

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Journal: Nature

Published: July 19, 2016

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

Journal: Breast cancer research and treatment

Published: October 07, 2014

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Journal: PloS one

Published: September 04, 2013

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Journal: Molecular cancer therapeutics

Published: June 28, 2013

Applying systems biology in drug discovery and development.

Applying systems biology in drug discovery and development.

Journal: Drug metabolism and drug interactions

Published: January 11, 2013

Analysis of sterol-regulatory element-binding protein 1c target genes in mouse liver during aging and high-fat diet.

Analysis of sterol-regulatory element-binding protein 1c target genes in mouse liver during aging and high-fat diet.

Journal: Journal of nutrigenetics and nutrigenomics

Published: July 30, 2012

RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension.

RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension.

Journal: American journal of physiology. Cell physiology

Published: February 11, 2012

Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).

Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience

Published: November 25, 2011

Showing 1-11 of 11

Last Updated: 09/26/2026